May 31st 2024
Results from a Phase I trial showed significant LDL-C reduction with AZD0780 plus statin therapy in treatment-naive patients with hypercholesterolemia.
Clinical Quiz: Nonstatin Therapies for LDL-C Lowering
March 25th 2024This clinical quiz will test your knowledge on the use of non-statin therapies for LDL-C lowering based on the American College of Cardiology's 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
Alirocumab Approved for Heterozygous Familial Hypercholesterolemia in Patients 8 Years and Older
March 11th 2024Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.
Elevated Lp(a) Levels Linked to Cardiovascular Event Risk, Regardless of ASCVD History
March 4th 2024The latest analysis of the Mass General Brigham Lp(a) Registry highlights Lp(a)'s independent association with cardiovascular events, with these associations apparent in patients regardless of baseline cardiovascular history.
Experts' Perspectives: Top Issue Facing Cardiology in 2024
February 21st 2024This 2024 American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.
CLEAR Outcomes Analysis Finds Bempedoic Acid Reduces Total Cardiovascular Events by 20%
January 18th 2024In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.
Bempedoic Acid Proves Cardiovascular Benefit Across Glycemic Spectrum in New Analysis
August 30th 2023A prespecified analysis of the CLEAR Outcomes trial assessing outcomes according to glycemic status suggests bempedoic acid provided similar relative benefits across the glycemic spectrum, but the greatest absolute benefits were observed in patients with diabetes.
Statin Therapy Could Reduce Cardiovascular Events in People with HIV
July 24th 2023New data presented at the 12th International AIDS Society Conference on HIV Science suggests use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events.
Study Suggests Bempedoic Acid Could Find Role in Primary Prevention
June 24th 2023An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.
CLEAR Outcomes Data at ENDO 2023 Provides Further Insight into Effects of Bempedoic Acid
June 15th 2023An analysis of data from the CLEAR Outcomes trial presented at ENDO 2023 suggests use of the non-statin lipid-lowering agent provided cardiovascular risk reduction comparable to statin therapy for each 1.0 mmol/L reduction in LDL-C.